BeiGene Ltd ADR BGNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
-
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
-
BeiGene Announces Updates to Commercial Leadership Team
-
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
-
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
-
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
-
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
-
BeiGene Names Rosenberg Finance Chief as Wang Departs
Trading Information
- Previous Close Price
- $233.64
- Day Range
- $243.06–248.16
- 52-Week Range
- $126.97–248.16
- Bid/Ask
- $238.50 / $246.35
- Market Cap
- $26.10 Bil
- Volume/Avg
- 607,526 / 290,144
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene’s revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 9,000
- Website
- https://www.beigene.com
Competitors
Valuation
|
Metric
|
BGNE
|
ABBV
|
01801
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 18.27 | — |
Price/Book Value | 7.34 | 50.92 | 7.10 |
Price/Sales | 7.88 | 6.30 | 10.12 |
Price/Cash Flow | — | 18.54 | 6,239.19 |
Price/Earnings
BGNE
ABBV
01801
Financial Strength
|
Metric
|
BGNE
|
ABBV
|
01801
|
|---|---|---|---|
Quick Ratio | 1.64 | 0.59 | 2.46 |
Current Ratio | 1.98 | 0.81 | 2.68 |
Interest Coverage | — | 3.51 | −19.08 |
Quick Ratio
BGNE
ABBV
01801
Profitability
|
Metric
|
BGNE
|
ABBV
|
01801
|
|---|---|---|---|
Return on Assets (Normalized) | −2.03% | 13.66% | −2.47% |
Return on Equity (Normalized) | −3.24% | 189.99% | −4.60% |
Return on Invested Capital (Normalized) | −4.24% | 27.06% | −5.53% |
Return on Assets
BGNE
ABBV
01801
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zfxlwmslk | Jjwv | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ycmhczn | Vpmbqm | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wqtvkndq | Sxpsmz | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yhvlchy | Dlplhkp | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Nnyscml | Ylyd | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ybxmvvd | Ywc | $28.5 Bil | |||
| Moderna Inc
MRNA
| Jhdlbyy | Bbmb | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Jdbfqgs | Tytw | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kqpmlzfg | Xzqntlr | $13.0 Bil | |||
| Incyte Corp
INCY
| Kxwvxvmvf | Wyltpkf | $12.9 Bil |
United States